Table 2.
The prevalence of HTN, the percentage of people tested and diagnosed with HTN among those aged 40–79 years.
|
| |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMONG INDIVIDUALS AGED 40–79 | |||||||||||||||||
|
| |||||||||||||||||
| PREVALENCE (%) | TESTED (%) | DIAGNOSED (%) | |||||||||||||||
|
|
|
|
|||||||||||||||
| MEN | WOMEN | MEN | WOMEN | MEN | WOMEN | ||||||||||||
|
|
|
|
|||||||||||||||
| % | % ASR | % | % ASR | SIG.b | % | % ASR | % | % ASR | SIG. | % | % ASR | % | % ASR | SIG. | |||
|
| |||||||||||||||||
| BE | 44.24 | 41.79 | 40.97 | 35.94 | n.s. | 93.03 | 92.51 | 94.27 | 93.66 | n.s. | 24.4 | 22.98 | 24.87 | 21.43 | n.s. | ||
|
| |||||||||||||||||
| SL | n.a.a | n.a.a | 23.40 | 23.04 | 11.49 | 11.76 | <0.001 | 15.65 | 13.99 | 9.97 | 8.07 | ||||||
|
| |||||||||||||||||
| CA | 31.41 | 30.79 | 35.13 | 32.51 | n.s. | 48.73 | 48.16 | 67.29 | 66.35 | <0.001 | 13.48 | 12.67 | 26.4 | 23.91 | |||
|
| |||||||||||||||||
| AMONG INDIVIDUALS WITH HTN AGED 40–79 | |||||||||||||||||
|
| |||||||||||||||||
| BE | 95.73 | 96.58 | 97.03 | 94.62 | n.s. | 42.1 | 42.45 | 53.02 | 49.32 | n.s. | |||||||
|
| |||||||||||||||||
| SL | n.a.a | n.a.a | n.a.a | n.a.a | |||||||||||||
|
| |||||||||||||||||
| CA | 68.13 | 64.54 | 87.76 | 85.21 | <0.001 | 42.45 | 32.5 | 75.16 | 69.32 | <0.001 | |||||||
|
| |||||||||||||||||
Notes: BE = Belgium, SL = Slovenia, CA = Cambodia; ASR = age-standardized rate; n.a. = not available; n.s. = not significant; ano valid estimations of HTN prevalence available for Slovenia and thus also not for ‘being tested’ and ‘diagnosed’ among those with HTN; bThe p-value is obtained by a logistic regression model.